Drug intelligence / Profile preview

APC310

Development stage: Preclinical
Lead developer: Andros Pharmaceuticals
Modality: Small Molecules
Administration: Topical

Overview

APC310 is a preclinical-stage topical anesthetic small molecule drug being developed by Andros Pharmaceuticals. It targets voltage-gated sodium channels to produce local anesthesia by inhibiting neuronal excitability. The drug is specifically designed for local administration to manage pain associated with clinical procedures such as intravenous catheter placement and venipuncture. APC310 utilizes Andros Pharmaceuticals' proprietary drug delivery platform, which focuses on novel topical dosage forms for pain management.

Targets

NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on APC310.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APC310.

Explore the full profile